fluzoparib + temozolomide

**Fluzoparib + temozolomide** is a combination therapy under clinical investigation for treating cancers such as *small cell lung cancer* and *Ewing sarcoma*. **Fluzoparib** is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), which blocks DNA repair in tumor cells, leading to cell death, particularly in tumors with homologous recombination repair deficiencies. **Temozolomide** is an oral alkylating agent that damages DNA through methylation, leading to cytotoxicity in rapidly dividing cancer cells. The synergistic rationale for combining fluzoparib with temozolomide is to enhance DNA damage and reduce the tumor's ability to repair it, potentially improving antitumor efficacy[1][2][5][7].

Brand names

AiRuiYiTemodarTemodal

Other names

fluzoparilfluzoparibtemozolomideTMZ